Have there been reports of suicidal thoughts or depression with GLP-1 medications?

The FDA has received post-marketing reports of suicidal thoughts and behaviors in patients using GLP-1 medications, though establishing causation is challenging. Clinical trials didn't show increased rates compared to placebo, but these trials may not capture rare psychiatric events. The European Medicines Agency (EMA) investigated and found no clear evidence of causal relationship, though they continue monitoring. Possible explanations include: GLP-1 receptors exist in the brain and could theoretically affect mood; rapid body changes may trigger psychological adjustment issues; pre-existing mental health conditions may fluctuate; or the reports represent background rates unrelated to medication. Patients with history of depression, suicidal ideation, or other mental health conditions should be monitored closely when starting GLP-1s. Report any new or worsening depression, suicidal thoughts, or unusual mood changes to your healthcare provider immediately. The benefits of GLP-1s generally outweigh risks for most patients, but mental health monitoring is important.